Dr Matthew Gregory, a corresponding author of the paper and CEO of
Isomerase Therapeutics Ltd, said: «The work described in this paper has important ramifications for the natural products field and synthetic biology generally.»
The collaboration was led by
Isomerase Therapeutics Ltd, and included the University of Cambridge, Pfizer, Roche and DSTL.